Advertisement Pharmaceutical Business review - Page 1598 of 5282 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 22, 2026

Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH

Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.

The trial assessed burosumab in paediatric patients from birth to one year. Credit: Inara Prusakova / Shutterstock.com.